CANCER AND LEUKEMIA GROUP B

本申请寻求对CALGB调查员活动的支持 通过位于查佩尔山的北卡罗来纳州大学参与 （UNC-CH）和附属机构在癌症方案和 白血病B组。在这个修改后的应用程序中，我们展示了增长 UNC-CH及其附属机构的临床试验和外联工作， 人居中心新的科学和行政贡献 调查员小组的研究和委员会，并扩大了 UNC-CH增加两个新附属机构的应计努力， 包括位于里士满的弗吉尼亚医学院及其附属机构 退伍军人管理局医院有可能增加一个 每年增加80-100例患者参与分组研究，包括所有 疾病部位以及骨髓移植。 我们新 UNC-CH的新成员已经开始广泛地做出贡献 通过设计和主持 白血病、免疫学和遗传学、化疗和 生物治疗、放射治疗、呼吸和乳腺委员会; 提出试点意见，以供小组验证和扩大;以及 鼓励更多的基础研究组成部分，以小组活动， 特别是在生物治疗、免疫学和分子生物学方面。 我们计划 通过保持一个活跃的克隆，继续为集团提供直接服务 获得批准并热情资助的过量参考实验室 在最近的审查中，并增加了生物治疗监测参考 UNC-CH实验室，用于群体生物治疗研究， 在最后一次赠款审查中提供资金。 我们进一步扩大了集团 通过增加独立资助的分子研究， 与GM-CSF组方案相关的骨髓增生异常 Edison Liu，我们癌症中心的新成员。 前任和新成员 我们的机构将扩大我们的贡献组科学和 科学和技术常设小组核心成员 行政委员会（Ozer，免疫学和遗传学核心，淋巴瘤 核心、化疗核心、化疗副主席、生物治疗主席; Rao，细胞遗传学核心; Evans，精神病学核心; Tepper，放射治疗 Core和Gavigan，数据审核核心，化疗/生物治疗核心，肿瘤学 护理核心。 UNC-CH新招聘的教师将扩大我们的 乳腺和外科委员会的承诺和小组参与 （J.Huth，J.Mohler）;放射治疗（J.Tepper，J.Rosenman，S.Sailer， J.罗利）、癌症预防（S.弗莱彻）和精神病学（D.埃文斯）。 因此，UNC-CH的调查人员及其工作人员加大了努力， 加强该地区的CALGB临床试验网络， 弗吉尼亚州的整个北卡罗来纳州和南卡罗来纳州， 增加收益并促进肿瘤学最新质量 照顾该地区。 继续参与拉丁美洲和加勒比地区法律援助和指导委员会， 一个重要的教育工具，为教师，研究员和内务人员在 UNC-CH以及私人执业的外展医生 血液学和内科肿瘤学参与我们的CALGB活动。

This application seeks support for the activities of CALGB investigators participating through the University of North Carolina at Chapel Hill (UNC-CH) and adjunct institutions in the programs of the Cancer and Leukemia Group B. In this revised application, we demonstrate the growth of the clinical trials and outreach efforts at UNC-CH and its adjuncts, the new scientific and administrative contributions of UNC-CH investigators to Group studies and committees, and the expansion of the UNC-CH accrual effort with the addition of two new adjunct institutions, including the Medical College of Virginia in Richmond and its affiliated Veterans Administration Hospital with the potential to accrue an additional 80-100 patients annually to group studies including all disease sites as well as bone marrow transplantation. Our newly recruited members at UNC-CH have already begun to contribute extensively to the intellectual productivity of the Group by designing and chairing new protocols in Leukemia, Immunology and Genetics, Chemotherapy and Biotherapy, Radiation Therapy, Respiratory and the Breast committees; by presenting pilot observations for group validation and expansion; and by stimulating more basic research components to group activities, particularly in biotherapy, immunology and molecular biology. We plan to continue direct service to the group by maintaining an active Clonal Excess Reference Laboratory that was approved and funded with enthusiasm during the recent review and have added a Biotherapy Monitoring Reference Laboratory at UNC-CH for Group biotherapy studies that received new funding in the last grant review. We have further broadened Group science by the addition of independently funded molecular studies in myelodysplasia in association with Group GM-CSF protocols designed by Edison Liu, a new recruit to our Cancer Center. Previous and new members of our institution will expand our contribution to Group science and administration as core members of standing Group scientific and administrative committees (Ozer, Immunology and Genetics core, Lymphoma core, Chemotherapy core, Chemotherapy vice-chair and Biotherapy chair; Rao, Cytogenetics core; Evans, Psychiatry core; Tepper, Radiation Therapy Core and Gavigan, Data Audit core, Chemotherapy/Biotherapy core, Oncology Nursing core. Newly recruited faculty at UNC-CH will expand our commitment and Group participation in the Breast and Surgery committees (J.Huth,J.Mohler); Radiation Therapy (J.Tepper, J.Rosenman, S.Sailer, J.Raleigh), Cancer Prevention (S.Fletcher) and Psychiatry (D.Evans). Investigators at UNC-CH and its adjuncts have therefore expanded efforts to strengthen the CALGB clinical trials network in the region from Virginia throughout North Carolina and into South Carolina both to increase accrual and to stimulate state-of-the-art quality of oncology care in the region. Ongoing participation in CALGB continues to serve as an important educational vehicle for faculty, fellows and housestaff at UNC-CH as well as the outreach physicians in private practice of hematology and medical oncology who participate in our CALGB activities.